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Background
Severe sepsis is typically characterized by initial cytokine-
mediated hyper-inﬂ ammation. Whether this hyper-
inﬂ ammatory phase is followed by immunosuppression is 
a subject of controversy. Animal studies suggest that 
multiple immune defects occur in sepsis, but data from 
humans remain conﬂ icting.
Methods
Objectives: To determine the association of sepsis with 
changes in host innate and adaptive immunity and to 
 examine potential mechanisms for putative immuno-
suppression.
Design: Rapid prospective postmortem spleen and lung 
tissue harvest and analysis within 120 minutes of death.
Setting: Intensive care units (ICUs) of academic medical 
centers.
Subjects: A convenience sample of 40 patients who died 
with active severe sepsis was taken over the course of 
2 years to characterize their immune status at the time of 
death. Control spleens (n  =  29) were obtained from 
patients who were declared brain dead or had emergent 
splenectomy due to trauma; control lungs (n = 20) were 
obtained from transplant donors or from lung cancer 
resections.
Interventions: None.
Outcomes: Cytokine secretion assays and immuno-
phenotyping of cell surface receptor-ligand expression 
proﬁ les were performed to identify potential mechanisms 
of immune dysfunction. Immunohistochemical staining 
was performed to evaluate the loss of immune eﬀ ector 
cells.
Results
Th e mean ages (standard deviations) of patients with 
sepsis and controls were 71.7 (15.9) and 52.7 
(15.0)  years, respectively. Patients with sepsis were in 
the ICU for a median of 8 days (range of 1 to 195 days), 
whereas control patients were in the ICU for not more 
than 4 days. Th e median duration of sepsis was 4 days 
(range of 1 to 40 days). Anti-CD3/anti-CD28-stimulated 
splenocytes from patients with sepsis, compared with 
those from controls, had signiﬁ cant reductions in 
cytokine secretion at 5  hours: tumor necrosis factor, 
5,361 (95% conﬁ dence interval (CI) 3,327 to 7,485) pg/
mL versus 418 (95% CI 98 to 738)  pg/mL; interferon-
gamma, 1,374 (95% CI 550 to 2,197) pg/mL versus 37.5 
(95% CI −5 to 80) pg/mL; interleukin-6, 3,691 (95% CI 
2,313 to 5,070) versus 365 (95% CI 87 to 642)  pg/mL; 
and interleukin-10, 633 (95% CI −269 to 1,534) versus 
58 (95% CI −39 to 156) pg/mL (P <0.001 for all). Th ere 
were similar reductions in 5-hour lipopolysaccharide-
stimulated cytokine secretion. Cyto kine secretion in 
patients with sepsis was generally less than 10% of that 
in controls, independently of age, dura tion of sepsis, 
corticosteroid use, and nutritional status. Despite 
diﬀ erences between spleen and lung, ﬂ ow cyto metric 
analysis showed increased expression of selected 
inhibitory receptors and ligands and expansion of sup-
pres sor cell populations in both organs. Unique diﬀ er-
ences in cellular inhibitory molecule expression existed 
in immune cells isolated from lungs of patients with 
sepsis versus patients with cancer and versus transplant 
donors. Immunohistochemical staining showed exten-
sive depletion of splenic CD4, CD8, and HLA-DR cells 
and expression of ligands for inhibitory receptors on 
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Conclusions
Patients who die in the ICU following sepsis compared 
with patients who die of non-sepsis etiologies have bio-
chemical, ﬂ ow cytometric, and immunohistochemical 
ﬁ ndings consistent with those of immunosuppression. 
Targeted immune-enhancing therapy may be a valid 
approach in selected patients with sepsis.
Commentary
In 1992, the American College of Chest Physicians and 
Society of Critical Care Medicine consensus conference 
deﬁ ned sepsis as the systemic inﬂ ammatory response 
syndrome occurring as a result of infection [1]. Clinical 
and immunologic discoveries have challenged this view 
of a hyper-inﬂ ammatory state, described as a ‘cytokine 
storm’ [2,3], in light of the failure of anti-inﬂ ammatory 
mediators, such as high-dose corticosteroids, tumor 
necrosis factor (TNF) antagonists, and interleukin-1 (IL-1) 
pathway inhibitors, to improve survival [4-6]. Subsequent 
theories have proposed that some patients may be 
immuno suppressed and the compensatory anti-inﬂ am-
matory response syndrome may predominate [7-9], lead-
ing to secondary infections and reactivation of dormant 
viruses [10,11]. Th ese ﬁ ndings have been based largely on 
experimental murine sepsis models [12,13] and small 
human studies, in which most measurements were 
obtained in the circulation.
Boomer and colleagues [14] conducted a compre hen-
sive assessment of immune dysfunction in human 
subjects who died of sepsis and multi-organ failure. 
Rather than focusing on circulating markers alone, the 
authors examined markers in tissues, including lungs 
since they are a common site for secondary infections. 
Th e authors identiﬁ ed multiple inhibitory mechanisms to 
explain the occurrence of immunosuppression, including 
dominance of inhibitory over activating receptors, 
expansion of suppressive cell types, and induction of 
inhibitory ligands on both antigen-presenting cells and 
tissue parenchymal cells.
Reduced expression of infl ammatory cytokines
Th e authors conﬁ rmed that immunosuppression occurs 
within tissues, and expression of key inﬂ ammatory 
markers, such as TNF-α, interferon-gamma (IFN-γ), and 
IL-6 and IL-10, was signiﬁ cantly decreased when 
splenocytes and cells from the lung were stimulated with 
anti-CD3/CD28, lipopolysaccharide, and phorbol esters.
Expansion of suppressor cell type
Regulatory T (Treg) cells, which suppress immune response, 
were increased in the spleen of patients with sepsis, and 
increased expression of cells with suppressor phenotype 
(myeloid-derived suppressor cells) was noted in the lung 
tissue.
Dominance of inhibitory over activating receptors and 
induction of inhibitory ligands
Th ere was reduced expression of CD28, a co-stimulatory 
signal that activates T cells and increases expression of 
PD-1 membrane protein. PD-1 negatively regulates T-
helper and cytotoxic cell proliferation in both lung and 
spleen. CTLA-4, a protein receptor that downregulates 
the immune system, was increased, whereas IL-7Ra, 
which mediates cell survival, was reduced in T cells, 
indicating dominance of inhibitory over activating 
receptors.
Antigen-presenting cells
HLA-DR, a receptor that presents peptide antigens to the 
immune system for the purpose of eliciting T-cell res-
ponse, was noted to be reduced. Immunohisto chemistry 
showed intense airway epithelial staining for herpes virus 
entry mediator (HVEM) and the receptor ligand for 
BTLA (a B- and T-cell attenuator protein expressed on 
T  cells mediating inhibitory function) on lung isolated 
from the majority of patients with sepsis. Th is is 
described mechanistically to mediate local immuno-
suppressive response in the lung in both pneumonia- and 
non-pneumonia-associated sepsis.
Th is is a novel study and provides clinical conﬁ rmation 
of previous experimental work showing profound 
immuno suppression in sepsis. Several ﬁ ndings of the 
study have important clinical implications. For instance, 
recovery of cytokine secretion at 22  hours was com-
parable for patients with sepsis and controls when 
removed from a septic milieu and suggests that immuno-
suppression may be reversible and indicates potential 
therapeutic possibilities.
Th is study has limitations. Despite an exhaustive 
assessment of immune markers, the sample size was 
small. Th ere was signiﬁ cant heterogeneity in the micro-
biologic etiology of patients with sepsis and control 
patients (transplant, trauma, and neurologic devastation). 
Whether results of this study can be generalized to most 
critically ill patients with sepsis is not clear. For example, 
sepsis patients who were alive were not included as a 
control group as it is diﬃ  cult to obtain tissue specimens 
in these patients. Many subjects in this study had a long 
intensive care unit course (range of 1 to 195  days) and 
represent those with prolonged critical illness [15,16].
Finally, several questions regarding immunosuppres-
sion remain poorly understood. What is its time course, 
and is it a dynamic process? Increased inﬂ ammation and 
immunosuppression may occur concurrently, and some 
studies suggest that immunosuppression may occur as 
early as hospital presentation. Which factors aﬀ ect 
immuno suppression? Th e authors found no diﬀ erence 
across age, duration of sepsis, and nutritional status. 
Given the small sample size, the eﬀ ect of these and other 
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factors could not be assessed. Finally, whether measure-
ments of immune markers in the tissues mirror those in 
the circulation is unclear. Many of the assays described in 
this study are not standardized and are diﬃ  cult to deploy 
in large multi-center clinical trials.
What are the study’s implications for the design of 
personalized strategies for patients with sepsis? First, 
recovery of cytokine secretion at 22  hours was 
comparable for patients with sepsis and controls when 
removed from a septic milieu. Th ese ﬁ ndings and a 
proof-of-concept study by Meisel and colleagues [17] 
suggest that immuno suppression could be reversed. 
Second, using anti-inﬂ ammatory agents, such as gluco-
corticoids, for all patients with sepsis may not be appro-
priate, and targeted therapy based on the state of their 
immune function should be considered. Several therapies 
may improve immuno sup pression. Th ese therapies could 
work on multiple pathways, such as IFN-γ, or target 
speciﬁ c pathways, such as PD-1 [18]. Instead of prior 
approaches in which these therapies are administered to 
broad populations, personalizing these therapies on the 
basis of immune proﬁ les should be considered.
Conclusions
Sepsis may represent a spectrum of dynamic immuno-
logic changes, which, if measurable, can direct therapies 
based on the preponderant mechanism. A subset of 
patients may still beneﬁ t from anti-inﬂ ammatory thera-
pies, whereas others may respond to immunostimulatory 
therapies. Th e stage is set for making further strides 
toward personalizing ‘immune therapy in sepsis’, hitherto 
a Shangri-La for clinicians and sepsis investigators.
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